-

Shareholder Alert: Robbins LLP Reminds Investors PaySign, Inc. (PAYS) Sued for Misleading Shareholders

SAN DIEGO & HENDERSON, Nev.--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP reminds investors that a purchaser of PaySign, Inc. (NASDAQ: PAYS) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between March 12, 2019 and March 15, 2020. PaySign provides prepaid card programs and processing services.

If you suffered a loss as a result of PaySign's misconduct, click here.

PaySign, Inc. (PAYS) Accused of Misleading Shareholders

According to the complaint, on March 12, 2019, PaySign attested to its accuracy over financial reporting and acknowledged the importance of its computer network systems in accurately processing its transactions and assured its internal controls were effective. These same statements were reiterated in its following quarterly reports for 1Q to 3Q 2019, each time affirming that there "were no changes in [its] internal controls over financial reporting that occurred during the quarter…that have materially affected…[its] internal control over financial reporting." Contrary to PaySign's assurances, on March 16, 2020, PaySign announced that it would be unable to timely file its annual report for fiscal year 2019, stating "the filing extension will provide the necessary time to complete [PaySign's] financial audit" and revealing it had identified "material weaknesses related to its assessment of internal controls over financial reporting and information technology general controls." Then, on March 31, 2020, PaySign once again announced that it would be delaying the release of its 2019 financial results. On this news, shares of PaySign fell 16% to close at $4.35.

If you purchased PaySign, Inc. (PAYS) securities between March 12, 2019 and March 15, 2020, you have until May 18, 2020, to ask the court to be appointed lead plaintiff for the class.

Contact us to learn more:
Leo Kandinov
(800) 350-6003
lkandinov@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested. Click here to receive free alerts from Stock Watch when companies engage in wrongdoing.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

Robbins LLP

NASDAQ:PAYS

Release Versions
$Cashtags

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Investor Notice: Robbins LLP Informs Investors of the Soleno Therapeutics, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Soleno Therapeutics (NASDAQ: SLNO) common stock between March 26, 2025 and November 4, 2025. Soleno is a pharmaceutical company focused on developing therapies for rare diseases. The Company’s only commercial product is diazoxide choline extended-release tablets (“DCCR”) for the treatment of hyperphagia in individuals afflicted with Prader-Wil...

Investor Notice: Robbins LLP Informs Investors of the Eos Energy Enterprises, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Eos Energy Enterprises, Inc. (NASDAQ: EOSE) securities between November 5, 2025 and February 26, 2026. Eos Energy designs, manufactures, and markets zinc-based battery energy storage systems intended for utility-scale commercial and industrial applications. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call...

Investor Notice: Robbins LLP Informs Investors of the Nektar Therapeutics Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Nektar Therapeutics (NASDAQ: NKTR) securities between February 26, 2025 and December 15, 2025. Nektar is a biopharmaceutical company focused on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders. The Company’s lead product candidate is rezpegaldesleukin (a/k/a REZPEG or NKTR-358), a n...
Back to Newsroom